Terms: = Brain cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Prognosis
89 results:
1. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract] [Full Text] [Related]
2. The Association of Immune Cell Infiltration with Metastasis Location in De Novo Metastatic Triple Negative Breast cancer: A Multicenter Cross-Sectional Study in Indonesia.
Tenggara JB; Rachman A; Prihartono J; Lisnawati L; Panigoro SS; Heriyanto DS; Steven R; Tandarto K; Juanputra S; Sudoyo AW
Acta Med Indones; 2023 Oct; 55(4):376-384. PubMed ID: 38213050
[TBL] [Abstract] [Full Text] [Related]
3. Radiogenomic landscape: Assessment of specific phagocytosis regulators in lower-grade gliomas.
Maimaiti A; Abulaiti A; Tang B; Dilixiati Y; Li X; Yakufu S; Wang Y; Jiang L; Shao H
Exp Biol Med (Maywood); 2023 Dec; 248(23):2289-2303. PubMed ID: 38062999
[TBL] [Abstract] [Full Text] [Related]
4. Predictive value of CCL2 in the prognosis and immunotherapy response of glioblastoma multiforme.
Deng L; Ren J; Li B; Wang Y; Jiang N; Wang Y; Cui H
BMC Genomics; 2023 Dec; 24(1):746. PubMed ID: 38057698
[TBL] [Abstract] [Full Text] [Related]
5. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract] [Full Text] [Related]
6. Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic.
Rios-Hoyo A; Arriola E
Front Immunol; 2023; 14():1221097. PubMed ID: 37876939
[TBL] [Abstract] [Full Text] [Related]
7. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.
Zhang XD; Liu ZY; Luo K; Wang XK; Wang MS; Huang S; Li RF
Sci Rep; 2023 Oct; 13(1):16859. PubMed ID: 37803063
[TBL] [Abstract] [Full Text] [Related]
8. Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives.
Duerinck J; Tuyaerts S; Movahedi K; Neyns B
Front Immunol; 2023; 14():1183641. PubMed ID: 37275902
[TBL] [Abstract] [Full Text] [Related]
9. Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma.
Chen L; Liu H; Li Y; Lin X; Xia S; Wanggou S; Li X
Front Immunol; 2023; 14():1105489. PubMed ID: 36845098
[TBL] [Abstract] [Full Text] [Related]
10. Systematic analysis identifies REST as an oncogenic and immunological biomarker in glioma.
Wang G; Yang X; Qi M; Li M; Dong M; Xu R; Zhang C
Sci Rep; 2023 Feb; 13(1):3023. PubMed ID: 36810892
[TBL] [Abstract] [Full Text] [Related]
11. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract] [Full Text] [Related]
12. Integrated machine learning methods identify FNDC3B as a potential prognostic biomarker and correlated with immune infiltrates in glioma.
Wang X; Huang Y; Li S; Zhang H
Front Immunol; 2022; 13():1027154. PubMed ID: 36275754
[TBL] [Abstract] [Full Text] [Related]
13. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract] [Full Text] [Related]
14. Characterization of Fatty Acid Metabolism-Related Genes Landscape for Predicting prognosis and Aiding Immunotherapy in Glioma Patients.
Jiang F; Luo F; Zeng N; Mao Y; Tang X; Wang J; Hu Y; Wu C
Front Immunol; 2022; 13():902143. PubMed ID: 35903107
[TBL] [Abstract] [Full Text] [Related]
15. Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The cancer Genome Atlas Data.
Zhong J; Xiang D; Ma X
Biomed Res Int; 2022; 2022():2309339. PubMed ID: 35845958
[TBL] [Abstract] [Full Text] [Related]
16. In Patients With Melanoma brain Metastases, Is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic.
Gritsch D; Mrugala MM; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2022 Sep; 27(5):290-297. PubMed ID: 35834790
[TBL] [Abstract] [Full Text] [Related]
17. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract] [Full Text] [Related]
18. Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning.
Liu XP; Jin X; Seyed Ahmadian S; Yang X; Tian SF; Cai YX; Chawla K; Snijders AM; Xia Y; van Diest PJ; Weiss WA; Mao JH; Li ZQ; Vogel H; Chang H
Neuro Oncol; 2023 Jan; 25(1):68-81. PubMed ID: 35716369
[TBL] [Abstract] [Full Text] [Related]
19. Melanoma brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents.
Moschos SJ
Am J Clin Dermatol; 2022 Jul; 23(4):523-545. PubMed ID: 35534670
[TBL] [Abstract] [Full Text] [Related]
20. Novel electrochemical immunosensor for O
Yang H; Ren J; Zhao M; Chen C; Wang F; Chen Z
Bioelectrochemistry; 2022 Aug; 146():108111. PubMed ID: 35378463
[TBL] [Abstract] [Full Text] [Related]
[Next]
